Condition (MeSH)
Malformations of Cortical Development
ClinicalTrials.gov lists 167 trials for Malformations of Cortical Development or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
1 more section with rows
7 of the 167 trials are tagged with Malformations of Cortical Development itself; the rest are tagged with a narrower condition beneath it.
When did Malformations of Cortical Development trials start? (30)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 15
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 6 |
| 2025 | 7 |
| 2024 | 9 |
| 2023 | 11 |
| 2022 | 15 |
| 2021 | 11 |
| 2020 | 4 |
| 2019 | 6 |
| 2018 | 9 |
| 2017 | 8 |
Showing 10 of 30 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 8 trials starting in 2026 and about 7 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 36 months from start to primary completion across 14 trials still running at the 2026-10-09 snapshot; registered median of 37 months across 85 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Malformations of Cortical Development trials in? (9)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 6 |
| Phase 1/2 | 12 |
| Phase 2 | 23 |
| Phase 2/3 | 4 |
| Phase 3 | 16 |
| Phase 4 | 6 |
| Not applicable | 25 |
| Observational | 74 |
| Expanded access | 1 |
How many Malformations of Cortical Development trials are recruiting? (9)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 4 |
| Recruiting | 35 |
| Enrolling by invitation | 3 |
| Active, not recruiting | 13 |
| Available | 1 |
Showing 5 of 9 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Malformations of Cortical Development trials? (8)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Jazz Pharmaceuticals | 6 |
| Novartis Pharmaceuticals | 6 |
| National Heart, Lung, and Blood Institute (NHLBI) | 5 |
| GRIN Therapeutics, Inc. | 3 |
| Institut National de la Santé Et de la Recherche Médicale, France | 3 |
Showing 5 of 8 sponsors.
Which drugs are being tested for Malformations of Cortical Development? (6)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| EVEROLIMUS | 16 |
| Sirolimus | 10 |
| Cannabidiol | 5 |
| Ganaxolone | 3 |
| Vigabatrin | 2 |
Showing 5 of 6 drugs.
Interventions as named in the registry (9)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| NPC-12G gel | 2 |
| Melatonin PR | 2 |
| EC Aspirin | 1 |
| AV078 | 1 |
| Skincerity plus sirolimus/rapamycin | 1 |
Showing 5 of 9 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Malformations of Cortical Development trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Seizure | 50 | 8 |
| Pneumonia | 37 | 9 |
| Neutrophil count decreased | 32 | 1 |
| Nervous system disorders | 27 | 1 |
| Status epilepticus | 19 | 5 |
Showing 5 of 10 adverse events.
Which publications cover Malformations of Cortical Development? (31)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Single-cell genotyping and transcriptomic profiling of mosaic focal cortical dysplasia. | Nature neuroscience | 2025 | Yes |
| Pilot study evaluating everolimus molecular mechanisms in tuberous sclerosis complex and focal cortical dysplasia. | PloS one | 2022 | Yes |
| Frequent SLC35A2 brain mosaicism in mild malformation of cortical development with oligodendroglial hyperplasia in epilepsy (MOGHE). | Acta neuropathologica communications | 2021 | Yes |
| Gradient of brain mosaic RHEB variants causes a continuum of cortical dysplasia. | Annals of clinical and translational neurology | 2021 | Yes |
| Novel variants in TUBA1A cause congenital fibrosis of the extraocular muscles with or without malformations of cortical brain development. | European journal of human genetics : EJHG | 2021 | Yes |
Showing 5 of 31 publications.
Prevalence (1)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Cerebral cortical dysplasia | Point prevalence | Unknown | Worldwide | Not stated | Unspecified |
Sub-conditions in MeSH (3)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: rare-disease identity.